{"transactions":[{"id":4615533,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":7278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":0,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":7278},"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615532,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":false,"shares":63548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":7278,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":63548},"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615531,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":false,"shares":54174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":70826,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":54174},"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615530,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":7278,"price":144.1,"value":1048759.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615529,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":7278,"price":21.58,"value":157059.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":530246,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615528,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":63548,"price":146.18,"value":9289446.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615527,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":true,"shares":63548,"price":21.58,"value":1371365.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":586516,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615526,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":54174,"price":145.87,"value":7902361.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":4615525,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T01:17:30.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":true,"shares":54174,"price":21.58,"value":1169074.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":577142,"source":{"system":"sec-edgar","filing":"0001104659-26-106831","document":"tm2625158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926106831/tm2625158-1_4seq1.xml","form_type":"4"}},{"id":3546694,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-08T21:14:07.000Z","date":"2026-09-03","kind":"gift","planned":false,"acquired":false,"shares":510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to relatives."}],"balance_after":522968,"source":{"system":"sec-edgar","filing":"0001104659-26-105955","document":"tm2624993-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926105955/tm2624993-1_4seq1.xml","form_type":"4"}},{"id":689598,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":false,"shares":34239,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":125000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":34239},"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689597,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":65761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":159239,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":65761},"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689596,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":34239,"price":148.52,"value":5085176.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689595,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-11","kind":"exercise","planned":true,"acquired":true,"shares":34239,"price":21.58,"value":738877.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":557717,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689594,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":65761,"price":149.11,"value":9805622.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":689593,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-12T22:43:08.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":65761,"price":21.58,"value":1419122.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."}],"balance_after":589239,"source":{"system":"sec-edgar","filing":"0001104659-26-095111","document":"tm2622954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926095111/tm2622954-1_4seq1.xml","form_type":"4"}},{"id":779637,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-15T00:06:46.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":225000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-26-061476","document":"tm2614674-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926061476/tm2614674-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-05-12"}},{"id":779636,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-15T00:06:46.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":75000,"price":100.12,"value":7509000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-061476","document":"tm2614674-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926061476/tm2614674-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-05-12"}},{"id":779635,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-15T00:06:46.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":true,"shares":75000,"price":21.58,"value":1618500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing."}],"balance_after":598478,"source":{"system":"sec-edgar","filing":"0001104659-26-061476","document":"tm2614674-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926061476/tm2614674-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-05-12"}},{"id":783010,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-12T23:28:00.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":225000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-26-059591","document":"tm2614444-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926059591/tm2614444-1_4seq1.xml","form_type":"4"}},{"id":783009,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-12T23:28:00.000Z","date":"2026-05-12","kind":"sale","planned":false,"acquired":false,"shares":75000,"price":100.12,"value":7509000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-059591","document":"tm2614444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926059591/tm2614444-1_4seq1.xml","form_type":"4"}},{"id":783008,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-12T23:28:00.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":true,"shares":75000,"price":21.58,"value":1618500.0,"ownership":{"direct":true},"balance_after":598478,"source":{"system":"sec-edgar","filing":"0001104659-26-059591","document":"tm2614444-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926059591/tm2614444-1_4seq1.xml","form_type":"4"}},{"id":801169,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-04-24T20:10:16.000Z","date":"2026-04-23","kind":"gift","planned":false,"acquired":false,"shares":1460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to family and friends."}],"balance_after":523478,"source":{"system":"sec-edgar","filing":"0001104659-26-048572","document":"tm2612651-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926048572/tm2612651-1_4seq1.xml","form_type":"4"}},{"id":828472,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":false,"shares":54641,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.58,"expiration_date":"2028-08-14","underlying":"Common Stock","underlying_shares":54641},"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828471,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-24","kind":"exercise","planned":false,"acquired":false,"shares":59,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":54641,"derivative":{"exercise_price":8.58,"expiration_date":"2028-08-14","underlying":"Common Stock","underlying_shares":59},"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828470,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-25","kind":"sale","planned":false,"acquired":false,"shares":54641,"price":101,"value":5518741.0,"ownership":{"direct":true},"balance_after":524938,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828469,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":true,"shares":54641,"price":8.58,"value":468819.78,"ownership":{"direct":true},"balance_after":579579,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828468,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-24","kind":"sale","planned":false,"acquired":false,"shares":59,"price":101,"value":5959.0,"ownership":{"direct":true},"balance_after":524938,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828467,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-24","kind":"exercise","planned":false,"acquired":true,"shares":59,"price":8.58,"value":506.22,"ownership":{"direct":true},"balance_after":524997,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":828466,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-25T23:23:16.000Z","date":"2026-03-23","kind":"gift","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to relatives."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026."}],"balance_after":524938,"source":{"system":"sec-edgar","filing":"0001104659-26-034736","document":"tm269861-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926034736/tm269861-1_4seq1.xml","form_type":"4"}},{"id":930273,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":false,"shares":4068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":300000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":4068},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930272,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":14205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These stock options are fully vested and will expire on October 11, 2026."}],"balance_after":304068,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":14205},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930271,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":false,"shares":10685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options are fully vested and will expire on April 29, 2026."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":10685},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930270,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"exercise","planned":false,"acquired":false,"shares":19315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options are fully vested and will expire on April 29, 2026."}],"balance_after":10685,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":19315},"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930269,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-27","kind":"sale","planned":false,"acquired":false,"shares":4068,"price":83.19,"value":338416.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.06 to $83.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930268,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-27","kind":"exercise","planned":false,"acquired":true,"shares":4068,"price":21.58,"value":87787.44,"ownership":{"direct":true},"balance_after":578573,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930267,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":14205,"price":84.05,"value":1193930.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.075. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930266,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":14205,"price":21.58,"value":306543.9,"ownership":{"direct":true},"balance_after":588710,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930265,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":10685,"price":84,"value":897540.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930264,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-26","kind":"exercise","planned":false,"acquired":true,"shares":10685,"price":4.21,"value":44983.85,"ownership":{"direct":true},"balance_after":585190,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930263,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":19315,"price":84.59,"value":1633855.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84.41 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930262,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"exercise","planned":false,"acquired":true,"shares":19315,"price":4.21,"value":81316.15,"ownership":{"direct":true},"balance_after":593820,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":930261,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T02:21:26.000Z","date":"2026-01-23","kind":"gift","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 23, 2026, the Reporting Person made a charitable donation of 6,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes."}],"balance_after":574505,"source":{"system":"sec-edgar","filing":"0001104659-26-007129","document":"tm264253-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926007129/tm264253-3_4seq1.xml","form_type":"4"}},{"id":934514,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-21T22:16:38.000Z","date":"2026-01-20","kind":"sale","planned":false,"acquired":false,"shares":34438,"price":82.48,"value":2840446.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":580505,"source":{"system":"sec-edgar","filing":"0001104659-26-005442","document":"tm263774-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926005442/tm263774-2_4seq1.xml","form_type":"4"}},{"id":947609,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T00:38:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":120200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":120200,"derivative":{"exercise_price":87.18,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":120200},"source":{"system":"sec-edgar","filing":"0001104659-26-001474","document":"tm262304-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926001474/tm262304-3_4seq1.xml","form_type":"4"}},{"id":947608,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-07T00:38:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":614943,"source":{"system":"sec-edgar","filing":"0001104659-26-001474","document":"tm262304-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465926001474/tm262304-3_4seq1.xml","form_type":"4"}},{"id":990482,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-24T21:01:18.000Z","date":"2025-11-21","kind":"gift","planned":false,"acquired":false,"shares":440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to his grandchild."}],"balance_after":519543,"source":{"system":"sec-edgar","filing":"0001104659-25-115399","document":"tm2532034-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925115399/tm2532034-1_4seq1.xml","form_type":"4"}},{"id":1036577,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-18T21:35:15.000Z","date":"2025-09-16","kind":"gift","planned":false,"acquired":false,"shares":620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to his son."}],"balance_after":519983,"source":{"system":"sec-edgar","filing":"0001104659-25-091352","document":"tm2526384-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925091352/tm2526384-1_4seq1.xml","form_type":"4"}},{"id":1080813,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-28T22:08:48.000Z","date":"2025-07-25","kind":"sale","planned":false,"acquired":false,"shares":10415,"price":54.78,"value":570533.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $54.75 to $54.82. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":520603,"source":{"system":"sec-edgar","filing":"0001104659-25-071262","document":"tm2521838-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925071262/tm2521838-1_4seq1.xml","form_type":"4"}},{"id":1082944,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-23T22:57:03.000Z","date":"2025-07-23","kind":"sale","planned":false,"acquired":false,"shares":17520,"price":54.79,"value":959920.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $54.75 to $55.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":531018,"source":{"system":"sec-edgar","filing":"0001104659-25-070104","document":"tm2521572-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925070104/tm2521572-1_4seq1.xml","form_type":"4"}},{"id":1082943,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-23T22:57:03.000Z","date":"2025-07-22","kind":"sale","planned":false,"acquired":false,"shares":22065,"price":55.05,"value":1214678.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":548538,"source":{"system":"sec-edgar","filing":"0001104659-25-070104","document":"tm2521572-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925070104/tm2521572-1_4seq1.xml","form_type":"4"}},{"id":1082942,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-23T22:57:03.000Z","date":"2025-07-21","kind":"sale","planned":false,"acquired":false,"shares":12859,"price":54.86,"value":705444.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of PSUs."}],"balance_after":570603,"source":{"system":"sec-edgar","filing":"0001104659-25-070104","document":"tm2521572-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925070104/tm2521572-1_4seq1.xml","form_type":"4"}},{"id":1082941,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-23T22:57:03.000Z","date":"2025-07-21","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents settlement by the Issuer of performance stock units (\"PSUs\") granted to the Reporting Person under the Issuer's 2016 Equity Incentive Plan on February 26, 2021, which vested based on the Issuer's achievement of corporate performance objectives."}],"balance_after":583462,"source":{"system":"sec-edgar","filing":"0001104659-25-070104","document":"tm2521572-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925070104/tm2521572-1_4seq1.xml","form_type":"4"}},{"id":1084865,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-18T20:01:15.000Z","date":"2025-07-16","kind":"gift","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 16, 2025, the Reporting Person made a charitable donation of 5,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 557 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 7, 2025."}],"balance_after":558462,"source":{"system":"sec-edgar","filing":"0001104659-25-069011","document":"tm2521210-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925069011/tm2521210-1_4seq1.xml","form_type":"4"}},{"id":1108489,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-17T20:01:12.000Z","date":"2025-06-16","kind":"gift","planned":false,"acquired":false,"shares":685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to his grandchildren."}],"balance_after":562905,"source":{"system":"sec-edgar","filing":"0001104659-25-060239","document":"tm2518201-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925060239/tm2518201-1_4seq1.xml","form_type":"4"}},{"id":1108488,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-17T20:01:12.000Z","date":"2025-06-13","kind":"gift","planned":false,"acquired":false,"shares":670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to his grandchildren."}],"balance_after":563590,"source":{"system":"sec-edgar","filing":"0001104659-25-060239","document":"tm2518201-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925060239/tm2518201-1_4seq1.xml","form_type":"4"}},{"id":1223524,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-06T01:02:40.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options are fully vested."}],"balance_after":30000,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-25-021045","document":"tm258430-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925021045/tm258430-1_4seq1.xml","form_type":"4"}},{"id":1223523,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-06T01:02:40.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":true,"shares":24000,"price":4.21,"value":101040.0,"ownership":{"direct":true},"balance_after":564260,"source":{"system":"sec-edgar","filing":"0001104659-25-021045","document":"tm258430-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925021045/tm258430-1_4seq1.xml","form_type":"4"}},{"id":1256502,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-20T22:25:23.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":5359,"price":38.18,"value":204606.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units."}],"balance_after":540260,"source":{"system":"sec-edgar","filing":"0001104659-25-015734","document":"tm257231-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925015734/tm257231-1_4seq1.xml","form_type":"4"}},{"id":1300545,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-17T22:46:26.000Z","date":"2025-01-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":12636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":545619,"source":{"system":"sec-edgar","filing":"0001104659-25-004570","document":"tm253633-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925004570/tm253633-2_4seq1.xml","form_type":"4"}},{"id":1311461,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T23:07:58.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":181472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":181472,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":181472},"source":{"system":"sec-edgar","filing":"0001104659-25-001429","document":"tm252003-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925001429/tm252003-4_4seq1.xml","form_type":"4"}},{"id":1311460,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-06T23:07:58.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":149800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":558255,"source":{"system":"sec-edgar","filing":"0001104659-25-001429","document":"tm252003-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465925001429/tm252003-4_4seq1.xml","form_type":"4"}},{"id":1349829,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-28T00:08:07.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":1727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options are fully vested."}],"balance_after":318273,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":1727},"source":{"system":"sec-edgar","filing":"0001104659-24-123806","document":"tm2429758-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924123806/tm2429758-1_4seq1.xml","form_type":"4"}},{"id":1349828,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-28T00:08:07.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":21480,"price":46.25,"value":993450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.49 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":408455,"source":{"system":"sec-edgar","filing":"0001104659-24-123806","document":"tm2429758-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924123806/tm2429758-1_4seq1.xml","form_type":"4"}},{"id":1349827,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-28T00:08:07.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":1727,"price":21.58,"value":37268.66,"ownership":{"direct":true},"balance_after":429935,"source":{"system":"sec-edgar","filing":"0001104659-24-123806","document":"tm2429758-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924123806/tm2429758-1_4seq1.xml","form_type":"4"}},{"id":1349826,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-28T00:08:07.000Z","date":"2024-11-25","kind":"gift","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On November 25, 2024, the Reporting Person made a charitable donation of 7,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes."}],"balance_after":428208,"source":{"system":"sec-edgar","filing":"0001104659-24-123806","document":"tm2429758-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924123806/tm2429758-1_4seq1.xml","form_type":"4"}},{"id":1349825,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-28T00:08:07.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":78520,"price":46.96,"value":3687299.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $46.50 to $47.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 313 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2024."}],"balance_after":435208,"source":{"system":"sec-edgar","filing":"0001104659-24-123806","document":"tm2429758-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924123806/tm2429758-1_4seq1.xml","form_type":"4"}},{"id":1356133,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-21T21:01:17.000Z","date":"2024-11-19","kind":"gift","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to his grandchild."}],"balance_after":513415,"source":{"system":"sec-edgar","filing":"0001104659-24-121501","document":"tm2429110-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924121501/tm2429110-1_4seq1.xml","form_type":"4"}},{"id":1477716,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-17T20:30:17.000Z","date":"2024-06-13","kind":"gift","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the Reporting Person to his grandchild."}],"balance_after":514415,"source":{"system":"sec-edgar","filing":"0001104659-24-072307","document":"tm2417453-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924072307/tm2417453-1_4seq1.xml","form_type":"4"}},{"id":1483869,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-11T20:30:21.000Z","date":"2024-06-07","kind":"sale","planned":true,"acquired":false,"shares":35000,"price":35.19,"value":1231650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 825 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024."}],"balance_after":515415,"source":{"system":"sec-edgar","filing":"0001104659-24-070419","document":"tm2416932-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924070419/tm2416932-1_4seq1.xml","form_type":"4"}},{"id":1554227,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-04-03T00:29:24.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":28.31,"value":707750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $27.69 to $28.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":549590,"source":{"system":"sec-edgar","filing":"0001104659-24-042744","document":"tm2410626-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924042744/tm2410626-1_4seq1.xml","form_type":"4"}},{"id":1607776,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-02T01:46:33.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":31.62,"value":948600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.28 to $32.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":574590,"source":{"system":"sec-edgar","filing":"0001104659-24-030159","document":"tm247765-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924030159/tm247765-3_4seq1.xml","form_type":"4"}},{"id":1612887,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-29T01:02:29.000Z","date":"2024-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":10915,"price":29.53,"value":322319.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units on February 26, 2024."}],"balance_after":604590,"source":{"system":"sec-edgar","filing":"0001104659-24-028888","document":"tm247552-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924028888/tm247552-2_4seq1.xml","form_type":"4"}},{"id":1634730,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-21T01:00:39.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":3717,"price":28.23,"value":104930.91,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 10,417 restricted stock units on February 15, 2024."}],"balance_after":615505,"source":{"system":"sec-edgar","filing":"0001104659-24-025685","document":"tm246687-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924025685/tm246687-1_4seq1.xml","form_type":"4"}},{"id":1688619,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T01:11:56.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":315250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":315250,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":315250},"source":{"system":"sec-edgar","filing":"0001104659-24-001492","document":"tm241954-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924001492/tm241954-4_4seq1.xml","form_type":"4"}},{"id":1688618,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-05T01:11:56.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":84875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":619222,"source":{"system":"sec-edgar","filing":"0001104659-24-001492","document":"tm241954-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465924001492/tm241954-4_4seq1.xml","form_type":"4"}},{"id":1709701,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-15T21:30:17.000Z","date":"2023-12-13","kind":"sale","planned":true,"acquired":false,"shares":75000,"price":20.08,"value":1506000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":534347,"source":{"system":"sec-edgar","filing":"0001104659-23-126419","document":"tm2333032-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923126419/tm2333032-1_4seq1.xml","form_type":"4"}},{"id":1757581,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-19T20:55:30.000Z","date":"2023-10-18","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":54000,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-23-110157","document":"tm2328807-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923110157/tm2328807-1_4seq1.xml","form_type":"4"}},{"id":1757580,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-19T20:55:30.000Z","date":"2023-10-18","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":4.21,"value":25260.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 401 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2023."}],"balance_after":609347,"source":{"system":"sec-edgar","filing":"0001104659-23-110157","document":"tm2328807-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923110157/tm2328807-1_4seq1.xml","form_type":"4"}},{"id":1870579,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-02T23:50:46.000Z","date":"2023-05-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":12165,"price":26.07,"value":317141.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."}],"balance_after":602946,"source":{"system":"sec-edgar","filing":"0001104659-23-067690","document":"tm2317724-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923067690/tm2317724-2_4seq1.xml","form_type":"4"}},{"id":1870578,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-02T23:50:46.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents settlement by the Issuer of performance stock units (\"PSUs\") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 1,663 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2023."}],"balance_after":615111,"source":{"system":"sec-edgar","filing":"0001104659-23-067690","document":"tm2317724-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923067690/tm2317724-2_4seq1.xml","form_type":"4"}},{"id":1870577,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-02T23:50:46.000Z","date":"2023-02-22","kind":"gift","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the \"Lock-up Date\") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date."}],"balance_after":583448,"source":{"system":"sec-edgar","filing":"0001104659-23-067690","document":"tm2317724-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923067690/tm2317724-2_4seq1.xml","form_type":"4"}},{"id":2052814,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-19T00:48:16.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":600000,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001104659-23-004721","document":"tm233829-7_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923004721/tm233829-7_4.xml","form_type":"4"}},{"id":2052813,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-19T00:48:16.000Z","date":"2022-12-28","kind":"gift","acquired":false,"shares":3116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 164 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2022."}],"balance_after":598096,"source":{"system":"sec-edgar","filing":"0001104659-23-004721","document":"tm233829-7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923004721/tm233829-7_4.xml","form_type":"4"}},{"id":2052812,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-19T00:48:16.000Z","date":"2022-05-04","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":581048,"source":{"system":"sec-edgar","filing":"0001104659-23-004721","document":"tm233829-7_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465923004721/tm233829-7_4.xml","form_type":"4"}},{"id":2175197,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-24T22:15:33.000Z","date":"2022-08-23","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is vested in full."}],"balance_after":60000,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-029621","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000089924322029621/doc4.xml","form_type":"4"}},{"id":2175196,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-24T22:15:33.000Z","date":"2022-08-23","kind":"exercise","acquired":true,"shares":20000,"price":4.21,"value":84200.0,"ownership":{"direct":true},"balance_after":604048,"source":{"system":"sec-edgar","filing":"0000899243-22-029621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000089924322029621/doc4.xml","form_type":"4"}},{"id":2282653,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-05T00:33:23.000Z","date":"2022-05-04","kind":"exercise","acquired":false,"shares":15742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is vested in full."}],"balance_after":80000,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":15742},"source":{"system":"sec-edgar","filing":"0001104659-22-055995","document":"tm2214526-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922055995/tm2214526-2_4seq1.xml","form_type":"4"}},{"id":2282652,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-05T00:33:23.000Z","date":"2022-05-04","kind":"exercise","acquired":true,"shares":15742,"price":4.21,"value":66273.82,"ownership":{"direct":true},"balance_after":584048,"source":{"system":"sec-edgar","filing":"0001104659-22-055995","document":"tm2214526-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922055995/tm2214526-2_4seq1.xml","form_type":"4"}},{"id":2290469,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-27T01:34:11.000Z","date":"2022-04-26","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":95742,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-22-050551","document":"tm2212815-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922050551/tm2212815-4_4seq1.xml","form_type":"4"}},{"id":2290468,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-27T01:34:11.000Z","date":"2022-04-26","kind":"exercise","acquired":true,"shares":30000,"price":4.21,"value":126300.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 459 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022."}],"balance_after":568306,"source":{"system":"sec-edgar","filing":"0001104659-22-050551","document":"tm2212815-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922050551/tm2212815-4_4seq1.xml","form_type":"4"}},{"id":2297134,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-15T00:09:49.000Z","date":"2022-04-14","kind":"exercise","acquired":false,"shares":34087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is vested in full."}],"balance_after":0,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":34087},"source":{"system":"sec-edgar","filing":"0001104659-22-046158","document":"tm2212815-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922046158/tm2212815-1_4seq1.xml","form_type":"4"}},{"id":2297133,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-15T00:09:49.000Z","date":"2022-04-14","kind":"exercise","acquired":true,"shares":34087,"price":1.89,"value":64424.43,"ownership":{"direct":true},"balance_after":537847,"source":{"system":"sec-edgar","filing":"0001104659-22-046158","document":"tm2212815-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922046158/tm2212815-1_4seq1.xml","form_type":"4"}},{"id":2361735,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-03T01:39:43.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":4648,"price":24.28,"value":112853.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 13,438 vested restricted stock units on February 28, 2022."}],"balance_after":503760,"source":{"system":"sec-edgar","filing":"0001104659-22-029520","document":"tm228264-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922029520/tm228264-2_4seq1.xml","form_type":"4"}},{"id":2389081,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-18T00:23:22.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":187500,"derivative":{"exercise_price":28.73,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001104659-22-024835","document":"tm227111-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922024835/tm227111-1_4seq1.xml","form_type":"4"}},{"id":2389080,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-18T00:23:22.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025."}],"balance_after":508408,"source":{"system":"sec-edgar","filing":"0001104659-22-024835","document":"tm227111-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465922024835/tm227111-1_4seq1.xml","form_type":"4"}},{"id":2459977,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-12-23T21:17:51.000Z","date":"2021-12-21","kind":"sale","acquired":false,"shares":15000,"price":32.1447,"value":482170.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.86 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":477158,"source":{"system":"sec-edgar","filing":"0001104659-21-153135","document":"tm2136222-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465921153135/tm2136222-1_4seq1.xml","form_type":"4"}},{"id":2563330,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-22T01:45:00.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":125742,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-21-118054","document":"tm2128192-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465921118054/tm2128192-1_4seq1.xml","form_type":"4"}},{"id":2563329,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-22T01:45:00.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":40000,"price":4.21,"value":168400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 1,014 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021 and September 9, 2021."}],"balance_after":492158,"source":{"system":"sec-edgar","filing":"0001104659-21-118054","document":"tm2128192-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000110465921118054/tm2128192-1_4seq1.xml","form_type":"4"}},{"id":2830172,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":24264,"kind":"person","name":"PATEL DINESH V PH D","position":1,"cik":"0001120477","reported_name":"PATEL DINESH V PH D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-26T23:33:13.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":225000,"derivative":{"exercise_price":23.57,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001209191-21-014981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120477/000120919121014981/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-26T23:33:13.000000Z,2830172"}